Puretech-backed Karuna makes Nasdaq debut with $89M IPO
Betting on the potential of two older drugs to fight Alzheimer’s and schizophrenia — Boston-based Karuna Therapeutics has priced its upsized initial public offering in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.